Tech Company Financing Transactions
Reata Pharmaceuticals Funding Round
On 7/6/2007, Reata Pharmaceuticals secured $25 million in Series E financing from CPMG and Novo Ventures.
Transaction Overview
Company Name
Announced On
7/6/2007
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series E
Investors
CPMG (Lead Investor) (Kent McGaughy)
Novo Ventures (Lead Investor) (Jack Nielsen)
Proceeds Purpose
Reata plans to use the proceeds from the financing to advance its pipeline, including funding multiple Phase 2 studies of the company's two lead development candidates, RTA 402 and RTA 744.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
2801 Gateway Dr. 150
Irving, TX 75063
USA
Irving, TX 75063
USA
Phone
Website
Email Address
Overview
Reata Pharmaceuticals, Inc. (NASDAQ: RETA) is a biopharmaceutical company focused on developing novel treatments for cancer, inflammation, and neurodegenerative diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Warren Huff
Chief Financial Officer
Jason Wilson
Chief Medical Officer
Colin Meyer
VP - Bus. Development
Dawn Bir
VP - Bus. Development
Keith Ward
VP - Finance
Elaine Castellanos
VP - General Counsel
Michael Wortley
VP - Marketing
David Chapman
VP - R & D
Christian Wigley
VP - Regulatory Affairs
Joel Proksch
Browse more venture capital transactions:
Prev: 7/6/2007: NephroGenex venture capital transaction
Next: 7/8/2007: Silent Communication venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs